Biberach, Germany

Silke Mühlau

This inventor holds 6 USPTO granted patents and 2 published patent applications and 5 EPO patents. Top assignees: Purdue Pharma L.p., Euro-Celtique S.a.. Active years: 2014-2019.

USPTO Granted Patents = 6 

% Patents Active = 50.0

 

Average Co-Inventor Count = 2.8

ph-index = 3

Forward Citations = 44(Granted Patents)


Location History:

  • Hamburg, DE (2015)
  • Biberach, DE (2014 - 2019)

Company Filing History:


Years Active: 2014-2019

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Silke Mühlau: Innovator in Pharmaceutical Preparations

Introduction

Silke Mühlau is a notable inventor based in Biberach, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in pain therapy. With a total of 6 patents, her work has had a substantial impact on medical treatments.

Latest Patents

One of her latest inventions is a pharmaceutical preparation containing oxycodone and naloxone. This invention concerns a storage stable pharmaceutical preparation that comprises oxycodone and naloxone for use in pain therapy. The active compounds are released from the preparation in a sustained, invariant, and independent manner, which enhances the effectiveness of pain management.

Career Highlights

Throughout her career, Silke has worked with prominent companies in the pharmaceutical industry, including Purdue Pharma L.P. and Euro-Celtique S.A. Her experience in these organizations has allowed her to develop innovative solutions that address critical healthcare needs.

Collaborations

Silke has collaborated with various professionals in her field, including Bianca Brögmann and Christof Spitzley. These partnerships have contributed to her success and the advancement of her inventions.

Conclusion

Silke Mühlau's contributions to pharmaceutical innovations demonstrate her commitment to improving pain management therapies. Her inventions continue to influence the medical field and provide valuable solutions for patients.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…